Spots Global Cancer Trial Database for dmmr
Every month we try and update this database with for dmmr cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy | NCT06414304 | Colorectal Canc... Colorectal Canc... MSI-H Colorecta... dMMR Colorectal... Cancer Colon Adenocarc... | 18 Years - | OncoAtlas LLC | ||
| A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer | NCT05890742 | MSI-H | Sintilimab IBI310&Sintilim... Radical surgery | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study | NCT04262089 | Uterine Cancer | Pembrolizumab (... | 18 Years - | University Medical Center Groningen | |
| Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy | NCT06414304 | Colorectal Canc... Colorectal Canc... MSI-H Colorecta... dMMR Colorectal... Cancer Colon Adenocarc... | 18 Years - | OncoAtlas LLC | ||
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | NCT02952989 | Carcinoma, Non-... Carcinoma, Rena... Breast Neoplasm... Urinary Bladder... Carcinoma, Squa... Colorectal Neop... Gastric Adenoca... Gastroesophagea... | SGN-2FF pembrolizumab | 18 Years - | Seagen Inc. | |
| Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study | NCT04262089 | Uterine Cancer | Pembrolizumab (... | 18 Years - | University Medical Center Groningen | |
| Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study | NCT06059495 | Adenocarcinoma ... Gastric Adenoca... | Dostarlimab | 18 Years - 75 Years | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors | NCT02715284 | Neoplasms | Dostarlimab | 18 Years - | Tesaro, Inc. | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors | NCT06004245 | Advanced Solid ... | RO7589831 | 18 Years - | Hoffmann-La Roche | |
| Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy | NCT05310643 | Metastatic Colo... | Nivolumab Ipilimumab | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | NCT02952989 | Carcinoma, Non-... Carcinoma, Rena... Breast Neoplasm... Urinary Bladder... Carcinoma, Squa... Colorectal Neop... Gastric Adenoca... Gastroesophagea... | SGN-2FF pembrolizumab | 18 Years - | Seagen Inc. | |
| KN035 for dMMR/MSI-H Advanced Solid Tumors | NCT03667170 | Solid Tumor | KN035 | 18 Years - | 3D Medicines | |
| Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer | NCT03827044 | POLE Exonucleas... Microsatellite ... Stage III Colon... | Avelumab | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Response to Immunotherapy in MMR-deficient Localized Colon Cancer | NCT05662527 | Colon Cancer | Pembrolizumab | 18 Years - | Rigshospitalet, Denmark | |
| Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy | NCT05310643 | Metastatic Colo... | Nivolumab Ipilimumab | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer | NCT05890742 | MSI-H | Sintilimab IBI310&Sintilim... Radical surgery | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer | NCT03638297 | Colorectal Canc... | PD-1 antibody +... | 18 Years - 80 Years | Sun Yat-sen University | |
| Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer | NCT03827044 | POLE Exonucleas... Microsatellite ... Stage III Colon... | Avelumab | 18 Years - | Royal Marsden NHS Foundation Trust | |
| KN035 for dMMR/MSI-H Advanced Solid Tumors | NCT03667170 | Solid Tumor | KN035 | 18 Years - | 3D Medicines | |
| Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study | NCT06059495 | Adenocarcinoma ... Gastric Adenoca... | Dostarlimab | 18 Years - 75 Years | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers | NCT05239546 | Colon Cancer dMMR Colorectal... | Dostarlimab | 18 Years - | University of Iowa |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
